NeuroVive out-licenses targeted LHON therapy

21 June 2018
2019_biotech_test_vial_discovery_big

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical (Nasdaq OMX: NVP) has entered into an exclusive licensing agreement with USA-based biotech BridgeBio Pharma for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program.

BridgeBio also announced that it has launched a subsidiary company Fortify Therapeutics to further develop this chemistry for local treatment of Leber's hereditary optic neuropathy (LHON), with an initial financial commitment of $20 million. NeuroVive's NVP015 program for other mitochondrial disorders will continue without any changes in focus or timelines.

The licensing agreement for this particular subset of the NVP015 program has a total deal value of around $60 million, which includes limited initial funding for research, and later milestone payments and a single digit royalty stream, that are dependent on successful development and market approval.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology